ReviewCell communication and signaling : CCS2025
Common mechanisms of Gut microbe-based strategies for the treatment of intestine-related diseases: based on multi-target interactions with the intestinal barrier.
Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gut microbiota metabolites in the immunoregulation of enteritis: research progress.Frontiers in immunology · 2025Pooled it
- Article
- Article
- Virus-Induced Intestinal Barrier Injury: Mechanisms and Therapeutic Perspectives.Veterinary sciences · 2026Review
- Gut microbiota in health and disease.Molecular biomedicine · 2026Review
- Dietary berberine supplementation regulates production performance, antioxidant capacity, and immunity of Wenchang chicken (Gallus gallus domestics).Poultry science · 2026Article
- Berberine in Inflammatory Bowel Disease: Integrative Regulation of the Microbiota-Immune-Barrier Axis.International journal of molecular sciences · 2026Review
- A Probiotic Mixture Neuralli™-CORE Attenuates DSS-Induced Colitis by Enhancing Gut Microbiota Resilience in Mice.International journal of molecular sciences · 2026Article
- Bacillus velezensis alleviates PMAnimal microbiome · 2026Article
- Reduced Neuroinflammation and Pain with a Functional Sourdough Bread Enriched with Legumes and Ancient Cereals in a Mouse Model of LPS-Induced Inflammation.International journal of molecular sciences · 2026Article
- Berberine Ameliorates DSS-Induced Colitis via Regulation of Mucosal Barrier Homeostasis and Mucin-Degrading Microbiota.International journal of molecular sciences · 2026Article
- Gut microbiota in Henoch-Schönlein purpura: from pathogenesis to therapeutic strategies.Frontiers in immunology · 2026Review
- Significant strain microdiversity in mother-infant dyad cohorts across ethnic groups reveals population specificity of bifidobacteria microbiota transmission.Frontiers in microbiology · 2026Article
- The gut microbiota-immune-brain axis in post-traumatic stress disorder: mechanistic integration and translational prospects.Frontiers in immunology · 2026Review
- Gut microbiota as a therapeutic target of Chinese herbal medicine in allergic rhinitis: the gut-nasal axis and immunity.Frontiers in physiology · 2026Review
- Targeting the Gut Microbiota with Herbal Compounds from Traditional Chinese Medicine: A Mechanistic Synthesis of a Novel Therapeutic Approach for Ulcerative Colitis.Journal of inflammation research · 2026Review
- Probiotic supplementation as a nutritional strategy for the prevention and management of sarcopenia in older adults.Frontiers in cellular and infection microbiology · 2026Article
- Gut microbiota-neuroimmune crosstalk in autoimmune encephalitis: mechanistic insights and therapeutic prospects.Frontiers in microbiology · 2026Review
- Gut microbiota-host adaptive immune interactions in type 2 diabetes mellitus: mechanisms, disease progression, and microbiota-based therapeutic strategies.Frontiers in microbiology · 2026Review
- Epigallocatechin gallate and lipid metabolism: intestinal fate, metabolite clusters, and regulatory mechanisms.Current research in food science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The concurrent occurrence and exacerbation of multiple diseases, including geriatric diseases and chronic diseases, impose a heavy burden on human health and medical expenses. Clarifying the common mechanisms of related multifarious diseases and developing preventive and therapeutic strategies with synergistic effects for multiple diseases are of great significance in alleviating the burden on the medical system and reducing patients' burden of drug metabolism. Recent studies have revealed that gut microbiota disorders and intestinal barrier damage, which consequently cause metabolic and immunological disorders, may be a common pathological basis underlying various intestinal-related diseases. In this review, we focus on the intestinal barrier function, summarizing the multi-target interactions and common mechanisms involved in diseases related to the gut such as ulcerative colitis, colorectal cancer, and type 2 diabetes. We identified gut microbe-based strategies, including probiotics, prebiotics, synbiotics, postbiotics, as well as potential targets in faecal microbiota transplant and berberine. The common mechanisms and key targets in the treatment of these diseases mainly include increasing the abundance of beneficial genera Bifidobacterium and Lactobacillus, increasing the levels of Short Chain Fatty Acids, restoring the intestinal mechanical barrier, and suppressing gut inflammation infiltration. We aim to provide a crucial basis and direction for the development of novel drugs with therapeutic effects for multiple diseases, thereby alleviating the patients' burden of medication and enhancing the efficacy of treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.